Nov 20 (Reuters) - Kyowa Kirin Co Ltd 4151.T:
KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE ZIFTOMENIB IN ACUTE LEUKEMIAS
KURA ONCOLOGY INC - TO RECEIVE $330 MILLION UPFRONT, UP TO $1.2 BILLION IN MILESTONES
KURA ONCOLOGY INC - TO INITIATE PHASE 3 FRONTLINE STUDIES IN AML IN 2025
Source text: ID:nGNX7fjytx
Further company coverage: 4151.T
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.